# Palbociclib

## IBRANCE 125mg

| TAH Drug Code      | [OIBR](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OIBR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer， advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer， advanced (with disease progression following endocrine therapy): Treatment of HR-positive， HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE， the recommended dose of fulvestrant is 500 mg administered on Days 1， 15， 29， and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | >10%: Dermatologic: Alopecia (18% to 33%)， skin rash (17% to 18%)， xeroderma (6% to 12%) Gastrointestinal: Decreased appetite (15% to 16%)， diarrhea (24% to 26%; grade 3: 1%)， nausea (34% to 35%; grade 3: <1%)， stomatitis (28% to 30%; grade 3: 1%)， vomiting (16% to 19%; grade 3: 1%) Hematologic & oncologic: Anemia (24% to 78%; grade 3: 3% to 6%; grade 4: <1%)， leukopenia (39% to 53%; grade 3: 24% to 30%; grade 4: 1%)， neutropenia (80% to 83%; grade 3: 55% to 56%; grade 4: 10% to 11%)， thrombocytopenia (16% to 23%; grade 3: 1% to 2%; grade 4: ?1%) Hepatic: Increased serum alanine aminotransferase (6% to 43%)， increased serum aspartate aminotransferase (8% to 52%) Infection: Infection (47% to 60%) Nervous system: Asthenia (8% to 17%)， fatigue (37% to 41%) Miscellaneous: Fever (12% to 13%) 1% to 10%: Gastrointestinal: Dysgeusia (7% to 10%) Hematologic & oncologic: Febrile neutropenia (?3%) Ophthalmic: Blurred vision (4% to 6%)， dry eye syndrome (4%)， increased lacrimation (6%) Respiratory: Epistaxis (7% to 9%) Postmarketing: Cardiovascular: Venous thromboembolism Dermatologic: Acute generalized exanthematous pustulosis， bullous rash， erythema multiforme， palmar-plantar erythrodysesthesia， Stevens-Johnson syndrome， vitiligo Hepatic: Hepatic injury (including hepatic encephalopathy， hepatitis， increased serum alkaline phosphatase， increased serum bilirubin， jaundice) Nervous system: Posterior reversible encephalopathy syndrome Neuromuscular & skeletal: Discoid lupus erythematous， subacute cutaneous lupus erythematous Respiratory: Interstitial lung disease， pneumonitis |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/palbociclib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## Ibrance 100mg

| TAH Drug Code      | [OIBR1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OIBR1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer， advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive， human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy Breast cancer， advanced (with disease progression following endocrine therapy): Treatment of HR-positive， HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.When given with IBRANCE， the recommended dose of fulvestrant is 500 mg administered on Days 1， 15， 29， and once monthly thereafter. Please refer to the full prescribing information of fulvestrant. Pre/perimenopausal women treated with the combination IBRANCE plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards. Recommended Dose Modification for Adverse Reactions: (Dose Level; Dose) Recommended starting dose: 125 mg/day; First dose reduction: 100 mg/day; Second dose reduction: 75 mg/day. Dose Modification and Management – Hematologic Toxicities: Monitor complete blood counts prior to the start of IBRANCE therapy and at the beginning of each cycle， as well as on Day 15 of the first 2 cycles， and as clinically indicated. For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles， monitor complete blood counts for subsequent cycles every 3 months， prior to the beginning of a cycle and as clinically indicated. (CTCAE Grade) Grade 1 or 2: No dose adjustment is required. Grade 3: Day 1 of cycle: Withhold IBRANCE， repeat complete blood count monitoring within 1 week. When recovered to Grade 2， start the next cycle at the same dose. Day 15 of first 2 cycles: If Grade 3 on Day 15， continue IBRANCE at current dose to complete cycle and repeat complete blood count on Day 22. If Grade 4 on Day 22， see Grade 4 dose modification guidelines below. Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3 neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles. Grade 3 neutropeniab with fever more than 38.5 oC and/or infection: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose. Grade 4: At any time: Withhold IBRANCE until recovery to Grade 2. Resume at the next lower dose. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to palbociclib or any component of the formulation. Use preparations containing St. John's Wort (or Hypericum).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common Dermatologic: Alopecia (18% to 33% )， Rash (17% to 18% ) Gastrointestinal: Constipation (20% )， Decrease in appetite (15% to 16% )， Diarrhea (24% to 26% )， Nausea (34% to 35% )， Stomatitis (28% to 30% )， Vomiting (16% to 19% ) Hematologic: Anemia， All Grades (24% to 30% )， Leukopenia， All Grades (39% to 53% )， Neutropenia， All Grades (80% to 83% )， Thrombocytopenia， All Grades (16% to 23% ) Immunologic: Infectious disease (47% to 60% ) Neurologic: Asthenia (8% to 13% )， Headache (26% )， Peripheral neuropathy (13% ) Respiratory: Bleeding from nose (6.7% to 9.2% )， Upper respiratory infection (31% ) Other: Asthenia (7.5% to 17% )， Fatigue (37% to 41% )， Fever (12% to 13% ) Serious Hematologic: Anemia， Grade 3 or 4 (Up to 5% )， Febrile neutropenia (0.9% to 2.5%)， Leukopenia， Grade 3 or 4 (Grade 3， 24% to 30%; Grade 4， up to 1% )， Neutropenia， Grade 3 or 4 (Grade 3， 55% to 56%; Grade 4， 10% to 11% )， Thrombocytopenia， Grade 3 or 4 (Up to 2% ) [仿單]20241224新增：(常見)肢端紅腫症候群、(常見)靜脈血栓栓塞，包含肺栓塞、深層靜脈血栓及周邊栓塞。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/palbociclib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

